Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
This article was originally published in The Pink Sheet Daily
Executive Summary
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).
You may also be interested in...
Barr Allegra-D Generic Receives Final Approval
A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.
Barr Allegra-D Generic Receives Final Approval
A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.
Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.